RxDoctor Payments Data

Michael Harris, MD

Internal Medicine · Bend, ORNPI 1023047503

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 17 payments — averaging $88.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$781
  • Novo Nordisk$351
  • Ionis Pharmaceuticals, Inc.$107
  • Regeneron Healthcare Solutions, Inc.$92
  • Corcept Therapeutics$75
  • Regeneron$61
  • plus $35 from 1 others

What the payments were for

  • Food & beverage$1,46798%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,502 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$319,595
Medicare patients
629
Services billed
8,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$253,317
OzempicSemaglutide171$240,507
JardianceEmpagliflozin169$188,316
TrulicityDulaglutide69$92,333
Repatha SureclickEvolocumab87$77,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$48,454
Ezetimibe1,046$45,545
XareltoRivaroxaban33$42,776
MounjaroTirzepatide34$38,714
Rosuvastatin Calcium1,324$37,700
Telmisartan484$18,684
Candesartan Cilexetil214$18,360
FarxigaDapagliflozin Propanediol18$18,286
Atorvastatin Calcium963$17,031
NexletolBempedoic Acid12$13,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$253,317213 claims
Novo NordiskOzempic$351$240,507171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →